Profile data is unavailable for this security.
About the company
LungLife AI, Inc. is a developer of clinical diagnostic solutions for lung cancer. The Company is engaged in the development and commercialization of its lung cancer early detection test. Using a minimally invasive blood draw, its LungLB test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. LungLB is a blood-based liquid biopsy assay that uses fluorescence in situ hybridization (FISH) and image analysis to identify circulating genetically abnormal cells (CGAC), which include circulating tumor cells (CTCs). The technique incorporates an artificial intelligence (AI)-derived image analysis strategy to identify unique cell populations reflective of the disease state under interrogation.
- Revenue in GBP (TTM)34.82k
- Net income in GBP-4.10m
- Incorporated2009
- Employees15.00
- LocationLungLife AI Inc2545 W. Hillcrest Drive, Suite 140THOUSAND OAKS 91320United StatesUSA
- Phone+1 (805) 409-9868
- Fax+1 (805) 855-2003
- Websitehttps://lunglifeai.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ReNeuron Group Plc | 249.00k | -5.07m | 1.93m | 34.00 | -- | 0.7966 | -- | 7.75 | -0.0888 | -0.0888 | 0.0044 | 0.0424 | 0.0246 | -- | 0.6442 | 7,323.53 | -50.10 | -43.12 | -101.09 | -58.50 | -- | -- | -2,037.35 | -714.73 | -- | -- | 0.1247 | -- | 31.51 | 65.26 | 44.18 | -- | -1.31 | -- |
| ValiRx Plc | 9.60k | -2.04m | 2.98m | 8.00 | -- | 0.7153 | -- | 310.19 | -0.0201 | -0.0201 | 0.00009 | 0.0315 | 0.0027 | -- | 0.0682 | -- | -59.88 | -50.57 | -58.27 | -54.77 | 85.00 | -- | -22,164.48 | -103,908.50 | 2.32 | -520.03 | 0.0075 | -- | -- | -- | 13.89 | -- | -1.13 | -- |
| TheraCryf PLC | 396.00k | -3.14m | 2.99m | 9.00 | -- | 0.822 | -- | 7.55 | -0.0114 | -0.0114 | 0.0014 | 0.0085 | 0.0858 | -- | 0.9766 | 44,000.00 | -67.93 | -42.50 | -81.69 | -46.66 | -- | -- | -792.17 | -1,482.46 | -- | -- | 0.00 | -- | -10.41 | -- | 22.41 | -- | -- | -- |
| Fusion Antibodies PLC | 1.58m | -2.84m | 3.19m | 50.00 | -- | 1.37 | -- | 2.02 | -0.0861 | -0.0861 | 0.0436 | 0.0245 | 0.5229 | 3.15 | 1.88 | 31,580.00 | -93.94 | -31.29 | -130.56 | -37.72 | -7.41 | 42.58 | -179.67 | -48.25 | 2.32 | -- | 0.0313 | -- | -39.55 | 1.52 | -116.33 | -- | -23.83 | -- |
| IXICO PLC | 6.00m | -1.87m | 4.59m | 89.00 | -- | 0.4576 | -- | 0.7656 | -0.0386 | -0.0386 | 0.1241 | 0.2076 | 0.4725 | -- | 3.54 | 67,415.73 | -14.69 | 4.35 | -16.58 | 5.33 | 46.90 | 62.09 | -31.10 | 6.61 | -- | -- | 0.0312 | 0.00 | -22.89 | 4.32 | -214.15 | -- | 92.12 | -- |
| ImmuPharma PLC | 0.00 | -2.92m | 5.82m | 5.00 | -- | 5.51 | -- | -- | -0.0081 | -0.0081 | 0.00 | 0.0025 | 0.00 | -- | -- | 0.00 | -87.27 | -86.13 | -163.24 | -106.39 | -- | -- | -- | -8,634.98 | -- | -8.61 | 0.00 | -- | -- | -- | 23.26 | -- | -- | -- |
| Cizzle Biotechnology Holdings PLC | 0.00 | -1.72m | 6.34m | 67.00 | -- | 3.86 | -- | -- | -0.0048 | -0.0048 | 0.00 | 0.0041 | 0.00 | -- | -- | -- | -76.69 | -144.15 | -82.81 | -167.75 | -- | -- | -- | -- | -- | -0.805 | 0.00 | -- | -- | -- | -88.27 | -- | -- | -- |
| Bivictrix Therapeutics PLC | 0.00 | -2.67m | 7.01m | 12.00 | -- | 3.04 | -- | -- | -0.0352 | -0.0352 | 0.00 | 0.0279 | 0.00 | -- | -- | 0.00 | -82.98 | -- | -98.20 | -- | -- | -- | -- | -- | -- | -- | 0.0809 | -- | -- | -- | -1.92 | -- | -- | -- |
| Genflow Biosciences PLC | 0.00 | -1.63m | 7.69m | 5.00 | -- | 8.86 | -- | -- | -0.0056 | -0.0056 | 0.00 | 0.0025 | 0.00 | -- | -- | 0.00 | -88.30 | -- | -105.34 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.97 | -- | -- | -- |
| Synairgen plc | 0.00 | -8.41m | 7.76m | 36.00 | -- | 0.6133 | -- | -- | -0.0418 | -0.0418 | 0.00 | 0.0629 | 0.00 | -- | -- | 0.00 | -44.55 | -54.01 | -51.06 | -60.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.35 | -- | -26.64 | -- |
| LungLife AI Inc | 34.82k | -4.10m | 8.58m | 15.00 | -- | 0.5585 | -- | 246.43 | -0.1608 | -0.1608 | 0.0014 | 0.2351 | 0.0038 | -- | 0.2831 | 2,321.65 | -44.11 | -- | -50.09 | -- | 100.00 | -- | -11,767.39 | -- | -- | -- | 0.0419 | -- | 91.67 | -- | 28.83 | -- | -- | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -6.69m | 17.36m | 17.00 | -- | 5.40 | -- | -- | -0.0061 | -0.0061 | 0.00 | 0.0024 | 0.00 | -- | -- | 0.00 | -101.47 | -82.19 | -112.85 | -95.97 | -- | -- | -- | -- | -- | -28.03 | 0.5144 | -- | -- | -- | -68.14 | -- | 36.68 | -- |
| Oxford Biodynamics PLC | 617.00k | -11.11m | 21.36m | 45.00 | -- | 8.54 | -- | 34.62 | -0.0643 | -0.0643 | 0.0035 | 0.008 | 0.0487 | 1.20 | 0.379 | 13,711.11 | -87.64 | -39.72 | -114.28 | -45.52 | 41.49 | -- | -1,800.32 | -1,324.62 | 0.6156 | -87.72 | 0.7873 | -- | 231.17 | -15.53 | -61.34 | -- | -1.60 | -- |
Data as of Aug 22 2024. Currency figures normalised to LungLife AI Inc's reporting currency: UK Pound GBX
12.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Unicorn Asset Management Ltd.as of 31 Jul 2024 | 1.75m | 6.87% |
| Lombard Odier Asset Management (Europe) Ltd.as of 22 Mar 2024 | 1.27m | 4.98% |
| SVM Asset Management Ltd.as of 31 Dec 2023 | 218.75k | 0.86% |
Data from 30 Apr 2024 - 31 Jul 2024Source: FactSet Research Systems Inc.
